TKT to Report Fourth Quarter and Year-End 2004 Financial Results on February 23, 2005
February 10 2005 - 9:17AM
PR Newswire (US)
TKT to Report Fourth Quarter and Year-End 2004 Financial Results on
February 23, 2005 CAMBRIDGE, Mass., Feb. 10 /PRNewswire-FirstCall/
-- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) will announce its
fourth quarter and year-end 2004 financial results on February 23,
2005 before the open of U.S. financial markets. In connection with
this announcement, TKT will host a conference call and live audio
webcast on February 23, 2005 at 10:00 a.m. Eastern Time to discuss
its fourth quarter and full year 2004 financial results and
financial outlook for 2005. Participants may access the call by
dialing (913) 981-5533. This call will also be broadcast live over
the Internet at http://www.tktx.com/ under the Investor Information
section. Please dial in 5 to 10 minutes prior to the scheduled
conference call time or log on to the website at least 15 minutes
prior to the call in order to register, download, and install any
necessary software. A replay of this conference call will be
available for two weeks, beginning February 23, 2005 at 1:00 p.m.
Eastern Time by dialing (719) 457- 0820 and using the access code
6847230. In addition, a replay of the webcast will be archived on
the TKT website under Events in the Investor Information section.
About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical
company primarily focused on researching, developing and
commercializing treatments for rare diseases caused by protein
deficiencies. Within this focus, the company markets Replagal(TM),
an enzyme replacement therapy for Fabry disease, and is developing
treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize
Dynepo(TM), its Gene- Activated(R) erythropoietin product for
anemia related to kidney disease, in the European Union. TKT was
founded in 1988 and is headquartered in Cambridge, Massachusetts,
with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's
website at http://www.tktx.com/. Gene-Activated(R) is a registered
trademark and Replagal(TM) is a trademark of Transkaryotic
Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA. For
More Information Contact: Daniella M. Lutz Corporate Communications
Manager (617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/ DATASOURCE: Transkaryotic Therapies,
Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager of
Transkaryotic Therapies, Inc., +1-617-349-0205 Web site:
http://www.tktx.com/ Company News On-Call:
http://www.prnewswire.com/comp/120657.html
Copyright
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jul 2023 to Jul 2024